相似文献
1
New Drugs Effective in the Systemic Treatment of Hepatocellular Carcinoma.新药对肝细胞癌全身治疗有效。
Clin Liver Dis (Hoboken). 2019 Sep 2;14(2):56-61. doi: 10.1002/cld.796. eCollection 2019 Aug.
2
[Systemic chemotherapy of hepatocellular carcinoma].[肝细胞癌的全身化疗]
Gan To Kagaku Ryoho. 1986 Apr;13(4 Pt 2):1584-8.
3
[New progress in the first-line treatment of advanced hepatocellular carcinoma].[晚期肝细胞癌一线治疗的新进展]
Zhonghua Gan Zang Bing Za Zhi. 2024 Feb 20;32(2):173-179. doi: 10.3760/cma.j.cn501113-20231114-00193.
4
Systemic Therapy in Metastatic Hepatocellular Carcinoma.转移性肝细胞癌的系统治疗。
Curr Gastroenterol Rep. 2022 May;24(5):65-71. doi: 10.1007/s11894-022-00842-9. Epub 2022 Apr 13.
5
APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024.2024年亚太肝脏研究学会肝细胞癌全身治疗临床实践指南
Hepatol Int. 2024 Dec;18(6):1661-1683. doi: 10.1007/s12072-024-10732-z. Epub 2024 Nov 21.
6
New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma.中晚期肝细胞癌的系统治疗新治疗模式。
Int J Clin Oncol. 2022 Jul;27(7):1110-1119. doi: 10.1007/s10147-022-02166-0. Epub 2022 May 8.
7
[Hepatocellular carcinoma].[肝细胞癌]
Gan To Kagaku Ryoho. 2010 Jul;37(7):1219-23.
8
[New Systemic Therapies for Advanced Hepatocellular Carcinoma].[晚期肝细胞癌的新型全身治疗方法]
Korean J Gastroenterol. 2019 Jan 25;73(1):10-15. doi: 10.4166/kjg.2019.73.1.10.
9
Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation.不可切除的早期、中期或晚期肝细胞癌的选择性内放射治疗：系统评价、网络荟萃分析和经济评估。
Health Technol Assess. 2020 Sep;24(48):1-264. doi: 10.3310/hta24480.
10
Hepatocellular carcinoma.肝细胞癌
Lancet. 2022 Oct 15;400(10360):1345-1362. doi: 10.1016/S0140-6736(22)01200-4. Epub 2022 Sep 6.
引用本文的文献
1
Antiproliferative Activity of -Acylhydrazone Derivative on Hepatocellular Carcinoma Cells Involves Transcriptional Regulation of Genes Required for G2/M Transition.β-酰腙衍生物对肝癌细胞的抗增殖活性涉及G2/M期转换所需基因的转录调控。
Biomedicines. 2024 Apr 18;12(4):892. doi: 10.3390/biomedicines12040892.
2
Synergism of small molecules targeting VDAC with sorafenib, regorafenib or lenvatinib on hepatocarcinoma cell proliferation and survival.小分子靶向 VDAC 与索拉非尼、瑞戈非尼或仑伐替尼联用对肝癌细胞增殖和存活的协同作用。
Eur J Pharmacol. 2023 Oct 15;957:176034. doi: 10.1016/j.ejphar.2023.176034. Epub 2023 Aug 29.
3
Non-alcoholic steatohepatitis and risk of hepatocellular carcinoma.非酒精性脂肪性肝炎与肝细胞癌风险。
Chin Med J (Engl). 2021 Dec 1;134(24):2911-2921. doi: 10.1097/CM9.0000000000001888.
4
Uncovering the Mechanisms of Cryptotanshinone as a Therapeutic Agent Against Hepatocellular Carcinoma.揭示隐丹参酮作为抗肝细胞癌治疗药物的作用机制
Front Pharmacol. 2020 Aug 13;11:1264. doi: 10.3389/fphar.2020.01264. eCollection 2020.
5
Treatment with a New Barbituric Acid Derivative Exerts Antiproliferative and Antimigratory Effects against Sorafenib Resistance in Hepatocellular Carcinoma.新型巴比妥酸衍生物治疗对肝癌索拉非尼耐药具有抗增殖和抗迁移作用。
Molecules. 2020 Jun 20;25(12):2856. doi: 10.3390/molecules25122856.
本文引用的文献
1
Molecular therapies and precision medicine for hepatocellular carcinoma.肝细胞癌的分子治疗和精准医学。
Nat Rev Clin Oncol. 2018 Oct;15(10):599-616. doi: 10.1038/s41571-018-0073-4.
2
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.卡博替尼治疗晚期和进展性肝细胞癌患者。
N Engl J Med. 2018 Jul 5;379(1):54-63. doi: 10.1056/NEJMoa1717002.
3
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.帕博利珠单抗治疗索拉非尼治疗后晚期肝细胞癌患者（KEYNOTE-224）：一项非随机、开放标签的 2 期试验。
Lancet Oncol. 2018 Jul;19(7):940-952. doi: 10.1016/S1470-2045(18)30351-6. Epub 2018 Jun 3.
4
SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma.SIRveNIB：索拉非尼对比选择性内放射治疗在亚太地区肝细胞癌患者中的应用。
J Clin Oncol. 2018 Jul 1;36(19):1913-1921. doi: 10.1200/JCO.2017.76.0892. Epub 2018 Mar 2.
5
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.乐伐替尼与索拉非尼用于不可切除肝细胞癌患者一线治疗的比较：一项随机、III 期非劣效性试验。
Lancet. 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1.
6
Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.钇[90Y]树脂微球选择性内放射治疗与索拉非尼治疗局部进展期不可切除肝细胞癌的疗效和安全性比较（SARAH）：一项开放标签随机对照 3 期临床试验。
Lancet Oncol. 2017 Dec;18(12):1624-1636. doi: 10.1016/S1470-2045(17)30683-6. Epub 2017 Oct 26.
7
Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies.索拉非尼治疗肝细胞癌患者获益的预后因素和预测因子：两项 III 期研究分析。
J Hepatol. 2017 Nov;67(5):999-1008. doi: 10.1016/j.jhep.2017.06.026. Epub 2017 Jul 4.
8
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.纳武利尤单抗治疗晚期肝细胞癌患者（CheckMate 040）：一项开放标签、非对照、1/2 期剂量递增和扩展试验。
Lancet. 2017 Jun 24;389(10088):2492-2502. doi: 10.1016/S0140-6736(17)31046-2. Epub 2017 Apr 20.
9
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.regorafenib 用于索拉非尼治疗后进展的肝细胞癌患者（RESORCE）：一项随机、双盲、安慰剂对照、3 期试验。
Lancet. 2017 Jan 7;389(10064):56-66. doi: 10.1016/S0140-6736(16)32453-9. Epub 2016 Dec 6.
10
Hepatocellular carcinoma.肝细胞癌。
Nat Rev Dis Primers. 2016 Apr 14;2:16018. doi: 10.1038/nrdp.2016.18.
Zotero 插件